Welcome to our dedicated page for Insmed news (Ticker: INSM), a resource for investors and traders seeking the latest updates and insights on Insmed stock.
News and press releases about Insmed Incorporated (INSM) provide insight into the company’s progress as a global biopharmaceutical organization focused on serious and rare diseases. Insmed regularly issues updates on its commercial performance, clinical trial milestones, regulatory decisions, and corporate initiatives across its respiratory, immunology & inflammation, and neuro & other rare disease programs.
Recent news has highlighted key events such as U.S. Food and Drug Administration approval of BRINSUPRI (brensocatib) for non-cystic fibrosis bronchiectasis, European Commission approval of BRINSUPRI for specified NCFB patients in the European Union, and detailed business updates around the commercial launch of BRINSUPRI and continued global growth of ARIKAYCE (amikacin liposome inhalation suspension). Investors can also follow announcements on the advancement of TPIP (treprostinil palmitil inhalation powder) into Phase 3 studies for pulmonary hypertension associated with interstitial lung disease and other pulmonary indications.
Insmed’s news flow also covers clinical data readouts from studies such as ASPEN and WILLOW in NCFB, the BiRCh and CEDAR trials evaluating brensocatib in additional neutrophil-mediated diseases, and early-stage developments in gene therapy programs INS1201, INS1202, and INS1203. Corporate communications include financial results, conference presentations at major healthcare and respiratory congresses, and updates on acquisitions such as INS1148, an investigational monoclonal antibody for respiratory and inflammatory conditions.
For followers of INSM stock, this news page offers a centralized view of Insmed’s ongoing commercial execution, regulatory interactions, and pipeline evolution. Regular updates help track how the company’s therapies and investigational candidates are progressing through development and reaching patient populations worldwide.
Insmed Incorporated (NASDAQ: INSM), a global biopharmaceutical company, has announced its participation in the 2025 Goldman Sachs Annual Global Healthcare Conference. The company's management will deliver a presentation on Wednesday, June 11, 2025, at 9:20 a.m. ET in Miami. Investors and interested parties can access the live webcast through Insmed's investor relations website section at www.insmed.com. The webcast recording will remain available for 30 days after the event concludes.
Insmed (Nasdaq: INSM), a global biopharmaceutical company focused on developing first- and best-in-class therapies for serious diseases, has announced its upcoming presentation at the BofA Securities 2025 Health Care Conference.
The presentation is scheduled for Tuesday, May 13, 2025, at 2:20 p.m. PT in Las Vegas. Interested parties can access the live webcast through the investor relations section of Insmed's website at www.insmed.com.
Key Details:
- Event: BofA Securities 2025 Health Care Conference
- Location: Las Vegas
- Date & Time: May 13, 2025, 2:20 p.m. PT
- Webcast Duration: Archive available for 30 days post-event
Insmed (INSM) has announced the redemption of all remaining outstanding 0.75% Convertible Senior Notes Due 2028, totaling $569.5 million. The redemption is scheduled for June 6, 2025, with a redemption price of approximately $1,000.10 per $1,000 principal amount, including accrued and unpaid interest.
Noteholders have the option to convert their notes into common stock until June 4, 2025. The current conversion rate is 30.7692 shares per $1,000 principal amount, equivalent to a conversion price of $32.50 per share. If all notes are converted, up to 17,523,336 shares of common stock will be issued.
Insmed (NASDAQ: INSM) announced the publication of positive Phase 3 ASPEN study results for brensocatib in the New England Journal of Medicine. The landmark study, the largest clinical trial ever conducted in bronchiectasis, demonstrated statistically significant results in treating non-cystic fibrosis bronchiectasis, a chronic inflammatory pulmonary disease.
The study met its primary endpoint with both 10mg and 25mg doses showing reduced annualized exacerbation rates (1.02 and 1.04) compared to placebo (1.29). The 25mg dose notably demonstrated a significant reduction in lung function decline. The drug was well-tolerated, with common side effects including COVID-19, nasopharyngitis, cough, and headache.
Brensocatib is currently under Priority Review with the FDA, with a target action date of August 12, 2025. If approved, it would become the first approved therapy for bronchiectasis and the first approved DPP1 inhibitor.
Insmed (Nasdaq: INSM) has scheduled its first-quarter 2025 financial results release and conference call for Thursday, May 8, 2025. The company will host an investor conference call at 8:00 a.m. ET on the same day to discuss the financial results and provide a business update.
Participants can join via phone by dialing (888) 210-2654 (U.S.) or (646) 960-0278 (international) using access code 7862189. The call will be webcast live on www.insmed.com. A replay will be available until May 15, 2025, through phone and a 90-day webcast archive on the company's website.
Insmed (INSM) will present 11 abstracts at the American Thoracic Society (ATS) 2025 International Conference in San Francisco from May 18-21, 2025. The presentations focus on their respiratory portfolio, featuring new analyses from the Phase 3 ASPEN study of brensocatib in bronchiectasis patients.
Key presentations include:
- Multiple prespecified subgroup analyses examining brensocatib's efficacy and safety
- Post-hoc analysis of lung function changes in bronchiectasis patients
- Health status improvements in patients with Mycobacterium Avium Complex (MAC) lung disease
- Clinical data from Phase 2a study of treprostinil palmitil inhalation powder in pulmonary hypertension
Chief Medical Officer Dr. Martina Flammer emphasized the significance of presenting new subgroup analyses from ASPEN, noting it as the largest Phase 3 clinical trial in bronchiectasis to date, particularly important given no treatments are specifically approved for this condition.
Insmed (INSM) has granted inducement awards to 18 new employees as approved by the company's Compensation Committee under NASDAQ Listing Rule 5635(c)(4). The awards, issued on March 7, 2025, consist of options to purchase 47,960 shares of Insmed common stock at an exercise price of $74.89 per share, matching the closing price on the Nasdaq Global Select Market on the grant date.
The stock options come with a 10-year term and feature a four-year vesting schedule. The vesting terms include 25% of shares vesting on the first anniversary, followed by 12.5% vesting every six months through the fourth anniversary, contingent on continued employment.
Insmed (INSM) announced that the FDA does not currently plan to hold an advisory committee meeting to discuss the New Drug Application (NDA) for brensocatib in patients with non-cystic fibrosis bronchiectasis. The FDA has maintained the application under Priority Review with a PDUFA target action date of August 12, 2025.
The NDA is supported by data from the ASPEN study, the largest Phase 3 study ever conducted in bronchiectasis patients. If approved, brensocatib would become the first approved treatment for bronchiectasis and the first in a new class of medicines called dipeptidyl peptidase 1 (DPP1) inhibitors for treating neutrophil-mediated diseases.